The Women's Interagency HIV Study: an Observational Cohort Brings Clinical Sciences to the Bench

The Women's Interagency HIV Study (WIHS) is an ongoing long-term observational study of 3,772 women who are either infected with human immunodeficiency virus (HIV) or considered to be at risk for acquiring HIV. Since 1994, the WIHS (pronounced like “wise”) has developed a large database and specimen repository that serve as resources for WIHS investigators as well as for nonaffiliated researchers working on HIV-related or HIV coinfection issues. The purpose of this report is to update researchers on the progress of the WIHS and to provide information on WIHS resources, the methods by which they were obtained, and background for any new potential researchers interested in conducting collaborative research through shared use of these resources.

[1]  R. Greenblatt,et al.  Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols , 2005, AIDS.

[2]  J. Nowakowski,et al.  A Decline in C6 Antibody Titer Occurs in Successfully Treated Patients with Culture-Confirmed Early Localized or Early Disseminated Lyme Borreliosis , 2005, Clinical Diagnostic Laboratory Immunology.

[3]  A. Thern,et al.  Comparison of the Antibodies in Lymphocyte Supernatant and Antibody-Secreting Cell Assays for Measuring Intestinal Mucosal Immune Response to a Novel Oral Typhoid Vaccine (M01ZH09) , 2005, Clinical Diagnostic Laboratory Immunology.

[4]  S. Preston‐Martin,et al.  Cancer Risk Among Participants in the Women’s Interagency HIV Study , 2004, Journal of acquired immune deficiency syndromes.

[5]  Mardge H. Cohen,et al.  Changes in sexual behavior among HIV-infected women after initiation of HAART. , 2004, American journal of public health.

[6]  Mardge H. Cohen,et al.  Medically eligible women who do not use HAART: the importance of abuse, drug use, and race. , 2004, American journal of public health.

[7]  J. Palefsky,et al.  Effect of antiretroviral therapy on the incidence of genital warts and vulvar neoplasia among women with the human immunodeficiency virus. , 2004, American journal of obstetrics and gynecology.

[8]  Mardge H. Cohen,et al.  Healthcare use by varied highly active antiretroviral therapy (HAART) strata: HAART use, discontinuation, and naivety , 2004, AIDS.

[9]  Mardge H. Cohen,et al.  The Prognostic Importance of Changes in CD4+ Cell Count and HIV-1 RNA Level in Women after Initiating Highly Active Antiretroviral Therapy , 2004, Annals of Internal Medicine.

[10]  S. Cole,et al.  Incidence of Lipoatrophy and Lipohypertrophy in the Women's Interagency HIV Study , 2003, Journal of acquired immune deficiency syndromes.

[11]  J. Goedert,et al.  Incident hepatitis C virus in women with human immunodeficiency virus infection. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  J. Robins,et al.  Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. , 2003, American journal of epidemiology.

[13]  K. Anastos,et al.  Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. , 2003, Journal of the National Cancer Institute.

[14]  J. Bremer,et al.  Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugs. , 2003, The Journal of infectious diseases.

[15]  R. Greenblatt,et al.  Protease Inhibitor Use and the Incidence of Diabetes Mellitus in a Large Cohort of HIV‐Infected Women , 2003, Journal of acquired immune deficiency syndromes.

[16]  Mardge H. Cohen,et al.  CC chemokine receptor 5 genotype and susceptibility to transmission of human immunodeficiency virus type 1 in women. , 2003, The Journal of infectious diseases.

[17]  Ann Duerr,et al.  Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. , 2003, The Journal of infectious diseases.

[18]  Alvaro Muñoz,et al.  Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease. , 2002, Archives of internal medicine.

[19]  R. Greenblatt,et al.  Prevalence and Correlates of Highly Active Antiretroviral Therapy Switching in the Women's Interagency HIV Study , 2002, Journal of acquired immune deficiency syndromes.

[20]  Mardge H. Cohen,et al.  Antibody-dependent cell-mediated cytotoxicity in cervical lavage fluids of human immunodeficiency virus type 1--infected women. , 2002, The Journal of infectious diseases.

[21]  Mardge H. Cohen,et al.  Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. , 2002, American journal of public health.

[22]  Mardge H. Cohen,et al.  Determinants of HIV-1 shedding in the genital tract of women , 2001, The Lancet.

[23]  Mardge H. Cohen,et al.  Retention of women enrolled in a prospective study of human immunodeficiency virus infection: impact of race, unstable housing, and use of human immunodeficiency virus therapy. , 2001, American journal of epidemiology.

[24]  D. Cotton.  Do we still need a cohort study of women with HIV infection? , 1998, Epidemiology.

[25]  Joseph Feldman,et al.  The Women's Interagency HIV Study , 1998 .

[26]  J. Phair,et al.  The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. , 1987, American journal of epidemiology.